Image_1_Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.tif
Sodium glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), heart failure (HF) or chronic kidney disease (CKD). However, whether or not the patients with coronary artery disease (CAD) have prognostic benefit from SGLT-2i treatment has not been fully studied. The purpose of this meta−analysis is to determine the prognostic benefit of SGLT-2i administration in CAD patients.
MethodsWe searched the PubMed, Embase and Cochrane Library from inception until October 15, 2021. We included randomized controlled trials (RCTs) reporting the effect of SGLT-2i on major adverse cardiovascular event (MACE), hospitalization for heart failure (HHF), cardiovascular (CV) death and cardiorenal parameters in CAD patients. Hazard ratio (HR) with 95% confidence interval (CI) and mean difference (MD) from trials were meta-analyzed using fixed-effects models.
ResultsNine trials enrolling 15,301 patients with CAD were included in the analyses. Overall, SGLT2i were associated with a reduced risk of MACE (HR: 0.84; 95% CI 0.74–0.95; I2 = 0%), HHF (HR: 0.69; 95% CI 0.58–0.83; I2 = 0%) and a composite of CV death or HHF (HR: 0.78; 95% CI 0.71–0.86; I2 = 37%) in CAD patients. Compared with control group, estimated glomerular filtration rate (eGFR) level decreased less in SGLT-2i group (mean difference [MD] = −3.60, 95% CI, −5.90 to −1.30, p = 0.002; I2 = 0%).
ConclusionsSGLT-2i can improve cardiorenal outcomes in CAD patients. Further RCTs and real world studies are need to investigate the effect of SGLT2i on CAD patients.
Systematic Review RegistrationPROSPERO, CRD42021258237.
History
References
- https://doi.org//10.1056/NEJMoa1311890
- https://doi.org//10.1016/S0140-6736(14)60921-1
- https://doi.org//10.1093/eurheartj/ehz425
- https://doi.org//10.1093/eurheartj/ehab368
- https://doi.org//10.1093/eurheartj/ehab484
- https://doi.org//10.2337/dc20-0059
- https://doi.org//10.7326/M20-2470
- https://doi.org//10.1056/NEJMoa1504720
- https://doi.org//10.1056/NEJMoa1611925
- https://doi.org//10.1056/NEJMoa1812389
- https://doi.org//10.1161/CIRCULATIONAHA.118.037778
- https://doi.org//10.1056/NEJMoa1911303
- https://doi.org//10.1056/NEJMoa2022190
- https://doi.org//10.1056/NEJMoa2024816
- https://doi.org//10.1016/S2213-8587(20)30344-2
- https://doi.org//10.7326/M14-2385
- https://doi.org//10.1136/bmj.d5928
- https://doi.org//10.1016/0197-2456(86)90046-2
- https://doi.org//10.1161/CIRCULATIONAHA.119.039996
- https://doi.org//10.1002/ejhf.2124
- https://doi.org//10.1056/NEJMoa2030183
- https://doi.org//10.1111/bcp.13903
- https://doi.org//10.1016/j.jcmg.2020.10.017
- https://doi.org//10.1002/ehf2.13509
- https://doi.org//10.1056/NEJMoa2107038
- https://doi.org//10.1016/S0140-6736(18)32590-X
- https://doi.org//10.1177/2047487318755531
- https://doi.org//10.1016/S2213-8587(16)00052-8
- https://doi.org//10.1016/S0140-6736(20)31824-9
- https://doi.org//10.1016/j.phrs.2020.105175
- https://doi.org//10.1210/clinem/dgaa534
- https://doi.org//10.1016/S2213-8587(19)30256-6
- https://doi.org//10.1371/journal.pmed.1002983
- https://doi.org//10.1186/s12933-018-0728-6
- https://doi.org//10.1016/S2213-8587(17)30104-3
- https://doi.org//10.1111/dom.13488
- https://doi.org//10.1002/ejhf.933
- https://doi.org//10.1177/2047487319829940
- https://doi.org//10.1016/j.jacc.2021.02.057
- https://doi.org//10.1186/s12872-018-0761-0
- https://doi.org//10.2337/dc14-1596
- https://doi.org//10.1016/j.cardfail.2017.09.014
CC BY 4.0